RIFATER
LOE ApproachingNDAORALTABLET
Approved
May 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFATER is an oral tablet combination product approved by Sanofi in 1994 for treatment of tuberculosis. The drug represents a fixed-dose combination approach to TB therapy. Specific mechanism of action and indications are not detailed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and resource allocation to managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest minimal active hiring for RIFATER roles, typical for a legacy product approaching LOE. Career opportunities are concentrated in defensive commercial and market access functions rather than growth-oriented roles.
Brand ManagerProduct Manager
Worked on RIFATER at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.